IDEXX Laboratories (IDXX) is coming off a year where trailing twelve month revenue reached about US$4.3 billion and basic EPS was US$13.17, with earnings up 19.3% over the past year. Over recent quarters, revenue has moved from US$954.3 million in Q3 2024 to US$1.1 billion in Q4 2025, while quarterly basic EPS has ranged between roughly US$2.64 and US$3.66, giving you a clear view of how the top and bottom line have been tracking into the latest Q1 2026 update. With net profit margins at 24.6% and trailing profitability described as high quality, investors are likely to focus on how these solid margins may influence expectations for the company’s next phase.

See our full analysis for IDEXX Laboratories.

With the latest results on the table, the next step is to see how these numbers line up against the most common narratives around IDEXX Laboratories and where the data may challenge those views.

Margins at 24.6% set the tone

• Over the last twelve months, IDEXX converted US$4.3b of revenue into US$1.1b of net income, which works out to a 24.6% net margin compared with 22.8% a year earlier.
• Consensus narrative points to diagnostic platforms and international expansion as key margin drivers, and the current 24.6% margin supports that view while also highlighting a tension with slowing US clinical visit growth of 2.5% in the recent quarter, which could make it harder to rely on visit volumes alone to sustain that profitability.
  • Recurring diagnostics and software revenue are described as supporting high margins, and the 19.3% earnings growth over the past year lines up with that story.
  • At the same time, the forecast revenue growth rate of 8.8% per year is more moderate than the margin profile might suggest, so investors need to weigh how much of the margin strength can come from mix and pricing rather than faster top line expansion.

Earnings growth outpaces revenue trends

• Trailing twelve month EPS sits at US$13.17 on US$4.3b of revenue, with earnings up 19.3% year over year versus forecast revenue growth of about 8.8% per year, which means earnings have grown faster than sales over the recent period.
• Bulls argue that adoption of new diagnostics, international coverage and software should keep earnings growing, and the current 8.9% five year average earnings growth and 9.75% forward earnings growth forecast give that case some support but also show it is not an aggressive step up from history.
  • Forecasts pointing to earnings growth of about 9.75% per year are only slightly above the five year 8.9% average, so the bullish view of a step change in profitability rests more on product mix than on a sharp acceleration in growth rates.
  • With analysts’ consensus target at US$715.21 versus a current share price of about US$562.97, bulls see room for upside, but that gap assumes the company can convert product launches into sustained earnings expansion beyond what is already in the trailing numbers.

On this set of numbers, bulls are effectively betting that IDEXX can keep turning moderate sales growth into higher earnings, not just grow faster overall, and that is where the biggest debate sits today. 🐂 IDEXX Laboratories Bull Case

Premium P/E of 42.2x keeps expectations high

• The stock trades on a P/E of 42.2x compared with 23.6x for the US Medical Equipment industry and 25.5x for peers, and the current share price of about US$562.97 is slightly above the US$556.43 DCF fair value estimate.
• Bears highlight that this premium multiple and the stretch versus DCF fair value leave less room for error, especially with forecasts calling for earnings growth around 9.75% per year and revenue growth of 8.8% per year rather than very rapid expansion.
  • The company’s high debt level adds another layer to that cautious view because it means part of the equity story rests on sustaining strong cash generation to comfortably service leverage.
  • Analysts still see upside to US$715.21, but the combination of a 42.2x P/E and a share price already a little above DCF fair value gives skeptics support for arguing that expectations for future execution are demanding.

For cautious investors, the key question is whether earnings and margins can keep justifying a P/E that is well ahead of both peers and the DCF fair value band, especially with higher debt in the background. 🐻 IDEXX Laboratories Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for IDEXX Laboratories on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of optimism and caution feels familiar, that is a signal to look at the numbers yourself and decide quickly where you stand. To weigh up what investors see as the key upsides and pressure points, start by checking the 3 key rewards and 2 important warning signs

See What Else Is Out There

Despite its strong margins, IDEXX currently trades at a high 42.2x P/E and carries elevated debt, alongside only moderate forecast growth, which may raise questions about downside risk.

If that combination of rich valuation and leverage feels uncomfortable, use the 72 resilient stocks with low risk scores to quickly find stocks with lower risk scores that may better align with your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.